Nuvation Bio Inc - Ordinary Shares - Class A
NUVB - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$1.67B
Close$
$1.24
73.8% downside
Current Fair Value
73.8% downsideOvervalued by 73.8% based on the discounted cash flow analysis.
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $1.67 Billion |
|---|---|
| Enterprise Value | $1.67 Billion |
| Earnings per Share | $-0.6 |
| Beta | 1.62 |
| Outstanding Shares | 348,770,000 |
Return
| Return on Equity | -59.02% |
|---|---|
| Return on Assets | -20.12% |
| Return on Invested Capital | -21.06% |
Valuation & Multiples
| P/E Ratio | -10.96 |
|---|---|
| PEG | -168.65 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | 9.82 |
| Enterprise Value to EBIT | -12.05 |
| Enterprise Value to Net Income | -12 |
| Total Debt to Enterprise | 0.16 |
| Debt to Equity | 1.03 |
Revenue Sources
No data
Last Earnings Call
Report Date
November 4, 2026
EPS Estimate
$-0.12
Consensus analyst estimateRevenue Estimate
$34.39 M
Consensus analyst estimateInstitutional Put/Call Ratio
Compares institutional put options with call options. At 0.00, the ratio is below 1, so institutions hold more calls than puts.
| Put/Call Ratio | 0.0000▼ 4.57% |
|---|---|
| Total Calls | -▼ 100.00% |
| Total Puts | -▼ 100.00% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 3.19%▼ 64.60% |
|---|---|
| Total Invested | $62.18M▼ 95.35% |
| Investors Holding | 41▼ 210.00% |
About Nuvation Bio Inc
36 employees
Nuvation Bio is a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates. Nuvation Bio's proprietary portfolio includes six novel and mechanistically ...